Notice of GM and proposed name change

Graft Polymer (UK) Plc (LON:GPL) announces its intention to change its name to Solvonis Therapeutics Plc, subject to approval of its shareholders at a general meeting of the Company (the "GM"), to be held at Eccleston Yards, 25 EP, Victoria, London, SW1W 9NF on 6 January, 2025 at 1:00pm GMT. This resolution will be proposed as a special resolution.

The proposed name, "Solvonis Therapeutics Plc" aligns more closely with the Company's strategic focus on developing intellectual property and co-developing therapeutics to address mental health and substance use disorders.

"Solvonis" reflect the Company's mission to improve outcomes for individuals and families affected by mental health and substance use disorders. The Company's initial focus is on trauma-related mental health disorders, such as post-traumatic stress disorder ("PTSD"). This mission will continue to be executed through the Company's previously stated plan of joint ventures, strategic partnerships, and mergers and acquisitions.

The proposed name change will be presented as a special resolution at the GM. Details of the GM, including the time and venue, will be included in the Notice of the General Meeting, which has been dispatched to shareholders today and made available on the Company's website.

The Board of Directors unanimously supports the proposed name change, believing it aligns with the Company's strategic objectives and serves the best interests of the Company and its shareholders. The Board recommends that shareholders vote in favour of the resolution to be proposed at the GM.

Continuing Progress with the Awakn Collaboration

The Company is pleased to report continued progress in its Aminoindane New Chemical Entity (NCE) collaboration with Awakn, originally announced on 18 July 2024. This collaboration represents an important step in the Company's efforts to advance innovative therapeutics for mental health. Results from the initial studies, conducted in partnership with Eurofins Discovery and the University of Nottingham, are expected to be reported imminently, marking a key development in the programme.

Charnwood Discovery, Awakn's selected synthesis partner (announced on 28 August 2024), was acquired by Concept Life Sciences on 5 November 2024. Awakn has confirmed that its collaboration will continue with Concept Life Sciences, ensuring a smooth transition for any further synthesis activities required to advance the Aminoindane NCE programme. These developments highlight the continued momentum and focus on delivering progress within this promising area of therapeutic research.

For more information, please visit www.graftpolymer.co.uk.